许秋然，博士，研究员/副主任医师，博士生导师。全省肿瘤分子诊断与个体化治疗研究重点实验室副主任、消化道肿瘤诊疗与药物研发省工程实验室副主任。省级人才计划领军人才，近年来，以第一或通讯作者发表SCI论文80余篇，包括Nat Commun、Research、Adv Funct Mater、Adv Sci、Mol Ther、Nucleic Acids Res、Mol Cancer、Cancer Lett、J Nanobiotechnology等国内外知名期刊。主持国家自然科学基金2项、省重点研发项目1项、省杰青项目1项、省杰青延续项目1项、省部共建重大项目1项、重点项目1项、中国博士后基金1项、其他省部级项目等5项，参与国家新药创制重大专项等10余项，授权发明专利2项，实用新型专利2项，获浙江省科技进步二等奖4项和浙江省医药科技进步一等奖1项。

 

博士：2011 年9 月-2014 年12 月，西安交通大学，外科学（肝胆外科）； 

硕士：2004 年9 月-2011 年7 月，西安交通大学，临床医学。
                   

 

1.2022年，肝胰恶性肿瘤精准诊疗创新技术的基础研究及临床推广应用，浙江省科技进步二等奖，排名2/9；

2.2020 年，肝癌创新诊疗的基础和临床应用研究，浙江省科技进步二等奖，排名2/9；

3.2021年，恶性血液病新型诊疗体系和预后模型的建立及应用，浙江省科技进步二等奖，排名4/9；

4.2016 年，肝胰恶性肿瘤分子标志物与治疗新技术的研究和应用，浙江省科技进步二等奖，排名4/11；        

 

全省肿瘤分子诊断与个体化治疗研究重点实验室副主任；消化道肿瘤诊疗与药物研发浙江省工程实验室副主任；中华医学会肝病学分会遗传代谢性肝病协作组第一届委员会委员；浙江省医学会常务理事；浙江省医学会分子医学分会常务委员；浙江省医学会科研管理分会常务委员； 《Annals of Translational Medicine》中青年编委；《Journal of Clinical and Translational Hepatology》中青年编委； 《Military Medical Research》期刊中青年编委；《中华肝胆外科手术学电子杂志》中青年编委；《中国普通外科杂志》中青年编委； 《临床与病理杂志》中青年编委。                        

 

1、国家自然科学基金面上项目，缺氧肿瘤微环境中TUFT1促进肝细胞癌生长和转移的机制研究，主持。

2、国家自然科学基金青年项目，HSP90通过调控PKM2磷酸化促进肝癌细胞糖酵解及增殖侵袭转移的作用机制研究，主持。

3、浙江省自然科学基金杰出青年基金延续项目，肿瘤细胞双硫死亡的蛋白泛素化修饰调控与靶向治疗研究，主持。

4、浙江省科技厅领雁项目，恶性肿瘤精准诊治新技术和新策略研究-肝细胞癌新型分子分型及免疫治疗新策略的探索，主持。

5、浙江省自然科学基金杰出青年项目，去泛素化酶MINDY4作为抗肝癌药物新靶标的可行性和干预研究，主持。

6、浙江省自然科学基金面上项目，Fbxw7通过泛素化蛋白酶解BCoR-L1蛋白调控肝癌细胞上皮间质转化的机制研究，主持。

7、浙江省卫健委省部共建重大项目，泛素缀合酶E2K作为抗胃癌药物新靶标的可行性及临床研究，主持。

8、浙江省医药科技计划省部共建重点项目，长链非编码RNA MCM3AP-AS1作为肝癌诊断新型生物标志物及特异性治疗靶点的研究，主持。

 

[1] Q. Xu, C. Yang, Y. Du, Y. Chen, H. Liu, M. Deng, H. Zhang, L. Zhang, T. Liu, Q. Liu, L. Wang, Z. Lou, H. Pei, AMPK regulates histone H2B O-GlcNAcylation, Nucleic Acids Res, 42 (2014) 5594-5604.

[2] Q. Xu, J. Tu, C. Dou, J. Zhang, L. Yang, X. Liu, K. Lei, Z. Liu, Y. Wang, L. Li, H. Bao, J. Wang, K. Tu, HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma, Mol Cancer, 16 (2017) 178.

[3] Y. Wang, L. Yang, T. Chen, X. Liu, Y. Guo, Q. Zhu, X. Tong, W. Yang, Q. Xu, D. Huang, K. Tu, A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis, Mol Cancer, 18 (2019) 28.

[4] Z. Xiao, Y. Liu, J. Zhao, L. Li, L. Hu, Q. Lu, Z. Zeng, X. Liu, D. Huang, W. Yang, Q. Xu, Long noncoding RNA LINC01123 promotes the proliferation and invasion of hepatocellular carcinoma cells by modulating the miR-34a-5p/TUFT1 axis, Int J Biol Sci, 16 (2020) 2296-2305.

[5] S. Gao, T. Chen, L. Li, X. Liu, Y. Liu, J. Zhao, Q. Lu, Z. Zeng, Q. Xu, D. Huang, K. Tu, Hypoxia-Inducible Ubiquitin Specific Peptidase 13 Contributes to Tumor Growth and Metastasis via Enhancing the Toll-Like Receptor 4/Myeloid Differentiation Primary Response Gene 88/Nuclear Factor-kappaB Pathway in Hepatocellular Carcinoma, Front Cell Dev Biol, 8 (2020) 587389.

[6] C. Shen, L. Ding, H. Mo, R. Liu, Q. Xu, K. Tu, Long noncoding RNA FIRRE contributes to the proliferation and glycolysis of hepatocellular carcinoma cells by enhancing PFKFB4 expression, J Cancer, 12 (2021) 4099-4108.

[7] Z. Zeng, Z. Shi, Y. Liu, J. Zhao, Q. Lu, J. Guo, X. Liu, D. Huang, Q. Xu, HIF-1alpha-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression, Biochem Biophys Res Commun, 566 (2021) 80-86.

[8] J. Wang, R. Liu, Y. Wang, H. Mo, Y. Niu, Q. Xu, Q. Liu, Repression of the miR-627-5p by histone deacetylase 3 contributes to hypoxia-induced hepatocellular carcinoma progression, J Cancer, 12 (2021) 5320-5330.

[9] J. Wang, R. Liu, H. Mo, X. Xiao, Q. Xu, W. Zhao, Deubiquitinase PSMD7 promotes the proliferation, invasion, and cisplatin resistance of gastric cancer cells by stabilizing RAD23B, Int J Biol Sci, 17 (2021) 3331-3342.

[10] Y. Liu, R. Liu, J. Zhao, Z. Zeng, Z. Shi, Q. Lu, J. Guo, L. Li, Y. Yao, X. Liu, Q. Xu, LncRNA TMEM220-AS1 suppresses hepatocellular carcinoma cell proliferation and invasion by regulating the TMEM220/beta-catenin axis, J Cancer, 12 (2021) 6805-6813.

[11] Z. Shi, R. Liu, Q. Lu, Z. Zeng, Y. Liu, J. Zhao, X. Liu, L. Li, H. Huang, Y. Yao, D. Huang, Q. Xu, UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKalpha2/mTOR pathway, Int J Med Sci, 18 (2021) 3749-3758.

[12] Y. Ma, X. Qu, C. Liu, Q. Xu, K. Tu, Metal-Organic Frameworks and Their Composites Towards Biomedical Applications, Front Mol Biosci, 8 (2021) 805228.

[13] M. Yang, C. Yang, Y. Zhang, X. Yan, Y. Ma, Y. Zhang, Y. Cao, Q. Xu, K. Tu, M. Zhang, An oral pH-activated "nano-bomb" carrier combined with berberine by regulating gene silencing and gut microbiota for site-specific treatment of ulcerative colitis, Biomater Sci, 10 (2022) 1053-1067.

[14] K. Fan, Z. Liu, M. Gao, K. Tu, Q. Xu, Y. Zhang, Targeting Nutrient Dependency in Cancer Treatment, Front Oncol, 12 (2022) 820173.

[15] X. Yan, C. Yang, M. Yang, Y. Ma, Y. Zhang, Y. Zhang, C. Liu, Q. Xu, K. Tu, M. Zhang, All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis, J Nanobiotechnology, 20 (2022) 99.

[16] X. Sun, R.Y. Zhang, F. Zhang, X.L. Hou, K. Cheng, C.Q. Li, X.T. Xie, Z.T. Zhong, B. Zhang, X.Q. Yang, W. Chen, B. Liu, Q.R. Xu, Y.D. Zhao, Multifunctional nanocarrier with self-catalytic production of nitric oxide for photothermal and gas-combined therapy of tumor, J Colloid Interface Sci, 621 (2022) 77-90.

[17] C. Liu, X. Yan, Y. Zhang, M. Yang, Y. Ma, Y. Zhang, Q. Xu, K. Tu, M. Zhang, Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy, J Nanobiotechnology, 20 (2022) 206.

[18] Z. Zhong, Y. Xu, J. Liu, C. Zhang, Z. Xiao, Y. Xia, Y. Wang, J. Wang, Q. Xu, Y. Lu, Clinicopathological study of gastric schwannoma and review of related literature, BMC Surg, 22 (2022) 159.

[19] J. Guo, F. Qiu, J. Zhao, Q. Lu, W. Fu, Q. Xu, D. Huang, Case Report: Retroperitoneal Sarcoma in Six Operations: Our Experience in Operative Management of Blood Vessels, Front Oncol, 12 (2022) 885033.

[20] Y. Xu, Y. Du, Q. Zheng, T. Zhou, B. Ye, Y. Wu, Q. Xu, X. Meng, Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy, Front Immunol, 13 (2022) 895110.

[21] Y. Xu, Q. Zheng, T. Zhou, B. Ye, Q. Xu, X. Meng, Necroptosis-Related LncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer, Front Oncol, 12 (2022) 887318.

[22] G. Shen, H. Wang, N. Zhu, Q. Lu, J. Liu, Q. Xu, D. Huang, HIF-1/2alpha-Activated RNF146 Enhances the Proliferation and Glycolysis of Hepatocellular Carcinoma Cells via the PTEN/AKT/mTOR Pathway, Front Cell Dev Biol, 10 (2022) 893888.

[23] J. Zhao, J. Guo, Y. Wang, Q. Ma, Y. Shi, F. Cheng, Q. Lu, W. Fu, G. Ouyang, J. Zhang, Q. Xu, X. Hu, Research Progress of DUB Enzyme in Hepatocellular Carcinoma, Front Oncol, 12 (2022) 920287.

[24] J. Guo, J. Zhao, W. Fu, Q. Xu, D. Huang, Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms, Front Immunol, 13 (2022) 918314.

[25] X. Hu, X. Lei, J. Guo, W. Fu, W. Sun, Q. Lu, W. Su, Q. Xu, K. Tu, The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer, Front Oncol, 12 (2022) 927640.

[26] Q. Lu, W. Fu, G. Ouyang, Q. Xu, D. Huang, A case of infectious mononucleosis complicated with spontaneous atraumatic splenic rapture caused by Epstein-Barr virus infection, J Med Virol, 94 (2022) 6127-6132.

[27] Q. Lu, H. Wang, X. Lei, Q. Ma, J. Zhao, W. Sun, C. Guo, D. Huang, Q. Xu, LncRNA ALKBH3-AS1 enhances ALKBH3 mRNA stability to promote hepatocellular carcinoma cell proliferation and invasion, J Cell Mol Med, 26 (2022) 5292-5302.

[28] N. Zhu, X. Chen, J. Zhao, L. Fang, Y. Yao, F. Zhou, L. Tao, Q. Xu, Hypoxia-induced LINC00674 facilitates hepatocellular carcinoma progression by activating the NOX1/mTOR signaling pathway, J Cancer, 13 (2022) 3177-3188.

[29] J. Guo, J. Zhao, Q. Xu, D. Huang, Resistance of Lenvatinib in Hepatocellular Carcinoma, Curr Cancer Drug Targets, 22 (2022) 865-878.

[30] X. Lei, X. Hu, Q. Lu, Y. Yao, W. Sun, Q. Ma, D. Huang, Q. Xu, UBE2K promotes the malignant progression of hepatocellular carcinoma by regulating c-Myc, Biochem Biophys Res Commun, 638 (2023) 210-218.

[31] X. Lei, X. Hu, Q. Lu, W. Fu, W. Sun, Q. Ma, D. Huang, Q. Xu, Ubiquitin?conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review), Oncol Rep, 49 (2023).

[32] X.L. Lei, K. Cheng, Y. Li, Z.T. Zhong, X.L. Hou, L.B. Song, F. Zhang, J.H. Wang, Y.D. Zhao, Q.R. Xu, The eradication of biofilm for therapy of bacterial infected chronic wound based on pH-responsive micelle of antimicrobial peptide derived biodegradable microneedle patch, Chemical Engineering Journal, 462 (2023) 142222.

[33] Y.J. Tang, K. Cheng, L.F. Tan, X.T. Xie, B. Zhang, W.M. Su, Y.D. Zhao, Q.R. Xu, pH and non-enzymatic glucose response at ultra-low concentration using submicrochannel heterogeneous membrane, Chemical Engineering Journal, 463 (2023) 142438.

[34] X. Yan, L. Meng, X. Zhang, Z. Deng, B. Gao, Y. Zhang, M. Yang, Y. Ma, Y. Zhang, K. Tu, M. Zhang, Q. Xu, Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses, Mol Ther, 31 (2023) 1383-1401.

[35] Q. Ma, Q. Lu, X. Lei, J. Zhao, W. Sun, D. Huang, Q. Zhu, Q. Xu, Relationship between HuR and tumor drug resistance, Clin Transl Oncol, 25 (2023) 1999-2014.

[36] J. Wang, H. Wang, M. Gao, Y. Zhang, L. Zhang, D. Huang, K. Tu, Q. Xu, The regulation of amino acid metabolism in tumor cell death: from the perspective of physiological functions, Apoptosis, 28 (2023) 1304-1314.

[37] F. Zhang, K. Cheng, Z.Y. Huang, X.L. Hou, X.S. Zhang, Z.T. Zhong, Y.G. Hu, X.L. Lei, Y. Li, P.J. Zhang, Y.D. Zhao, Q.R. Xu, Tumor Microenvironment-Responsive Nanocarrier Based on VOx Nanozyme Amplify Oxidative Stress for Tumor Therapy, Adv Funct Mater, 33 (2023) 2212740.

[38] J. Guo, J. Zhao, Q. Xu, D. Huang, MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib, BMC Cancer, 23 (2023) 967.

 

有多年研究生带教经验，学生多次获得国家奖学金。